International reports reinforce need to redouble China anti-counterfeiting efforts, says global hologram trade body
15 September 2014 | By Issued on behalf of the IHMA by MHW PR Ltd
Millions of fakes pouring into EU, US and Japanese markets...
List view / Grid view
News
Lilly announces CYRAMZA™ Phase III second-line colorectal cancer trial meets primary endpoint of overall survival
12 September 2014 | By Eli Lilly and Company
Eli Lilly and Company announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival...
Scientific founder of Intercept Pharmaceuticals joins Tiziana Life Sciences
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
Abbott announces new $3 billion share repurchase program, declares dividend
12 September 2014 | By Abbott
Abbott's board of directors has approved a new share repurchase program and declared a quarterly common dividend...
Intarcia announces two presentations at 50th EASD meeting: confirms pivotal phase 3 data announcement for ITCA 650 in type 2 diabetes in 4q
12 September 2014 | By Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15-19...
Rigaku Raman Technologies to showcase world’s first customizable handheld Raman analyzer for accurate and comprehensive raw material ID at CPhI 2014
12 September 2014 | By Rigaku
Rigaku Raman Technologies, a leading pioneer of handheld and portable Raman spectrometers, will be showcasing its new generation handheld Raman analyzer for raw material identification (RMID) in booth 1C82 at CPhI Worldwide 2014...
AAA acquires GE Healthcare’s FDG-PET Radiopharmaceutical Business in Italy
11 September 2014 | By Advanced Accelerator Applications and GE Healthcare
Advanced Accelerator Applications strengthens its position in the Italian PET Radiopharmaceutical Market...
Waters unveils global mass spectrometry headquarters in the UK’s North West
11 September 2014 | By Waters
Waters Corporation celebrated the official opening of its new, custom-built mass spectrometry headquarters in Wilmslow, UK, confirming the company's commitment to innovation and the expanded usage of mass spectrometry...
Futura Medical plc interim results for the six months ended 30 June 2014
11 September 2014 | By Futura Medical plc
Futura Medical plc is pleased to announce its interim results for the six months ended 30 June 2014...
European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa
10 September 2014 | By GlaxoSmithKline
GSK announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases in Africa, as part of GSK’s Africa NCD Open Lab initiative...
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression
10 September 2014 | By Novartis
Novartis announced that new data presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, reinforces the clinical importance of measuring brain shrinkage (brain volume loss) in multiple sclerosis...
FDA Advisory Committee recommends against approval of Actavis’ Nebivolol/Valsartan fixed-dose combination NDA for treatment of hypertension
10 September 2014 | By Actavis
Actavis plc confirmed that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension...
DPT Laboratories acquires Meda Pharmaceuticals’ Lakewood, New Jersey, Location
10 September 2014 | By DPT Laboratories
DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities...
Mundipharma announces results of pivotal phase III study for flutiform® in paediatric asthma
8 September 2014 | By Mundipharma
New data from a randomised, multicentre, phase III study, being presented at the European Respiratory Society (ERS) annual congress in Munich, Germany, supports the potential of flutiform® for the treatment of paediatric asthma...
